论文部分内容阅读
目的:观察急性脑梗死患者应用尼莫地平进行脑保护的治疗效果。方法:将60例急性脑梗死患者随机均分为尼莫地平组和对照组,于治疗前和治疗后第14、30天采用Barthel指数(BI)量表评价;并于治疗前和治疗后第3、7天测血清基质金属蛋白酶9(MMP-9)水平。结果:治疗后第14、30天尼莫地平组和对照组BI评分分别为(67.98±12.67)分vs(.89.02±10.37)分,(60.06±11.89)分vs(.78.83±13.02)分,2组比较差异有统计学意义(P<0.05或P<0.01);治疗后第3、7天尼莫地平组和对照组血清MMP-9浓度分别为(238.73±123.37)mg·mL-1vs(.86.23±29.45)mg·mL-1,(299.83±119.47)mg·mL-1vs(.105.56±31.17)mg·mL-1,2组比较差异有统计学意义(P<0.05或P<0.01)。结论:尼莫地平治疗急性脑梗死患者可有效地改善急性缺血性脑损害患者的神经功能缺损,疗效较好。
Objective: To observe the effect of nimodipine on cerebral protection in patients with acute cerebral infarction. Methods: Sixty patients with acute cerebral infarction were randomly divided into nimodipine group and control group. Barthel Index (BI) scale was used before and after treatment on the 14th and 30th days. Serum levels of matrix metalloproteinase 9 (MMP-9) were measured on days 7 and 7. Results: The BI scores of nimodipine group and control group were (67.98 ± 12.67) vs (.89.02 ± 10.37), (60.06 ± 11.89) vs (.78.83 ± 13.02) (P <0.05 or P <0.01). The levels of MMP-9 in nimodipine group and control group on the 3rd and 7th day after treatment were (238.73 ± 123.37) mg · mL-1vs .86.23 ± 29.45) mg · mL-1, (299.83 ± 119.47) mg · mL-1vs (.105.56 ± 31.17) mg · mL-1 and 2 groups showed statistically significant difference (P <0.05 or P <0.01) . Conclusion: Nimodipine in patients with acute cerebral infarction can effectively improve the neurological deficits in patients with acute ischemic brain damage, the effect is better.